ClinicalTrials.gg
RecruitingNCT02973828Updated Nov 6, 2026

PRIMER: Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided Radiotherapy

An observational study in Adenocarcinoma, sponsored by Institute of Cancer Research, United Kingdom. Recruiting at 1 site in United Kingdom. Open to participants aged 3 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Institute of Cancer Research, United Kingdom · Observational

How we know

From the registry’s dates

  • Started Oct 2017; still recruiting 9 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
173
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Adenocarcinoma with a site in United Kingdom — 9 open to participants now, 15 under way, 5 of them phase 3. Adenocarcinoma · United Kingdom.

Started
2017
with 2 others
Observational
4 of 53
1 open now
Primary completion
2026-12
later than 5 of 14 live
Registered
32nd of 53
by date
Lead sponsor
2 of 53
Institute of Cancer Research, United Kingdom

Among the 53 studies in Adenocarcinoma with a site in United Kingdom, this one is one of 3 that started in 2017, is one of 4 observational ones, reaches primary completion later than 5 of the 14 other live ones, and was the 32nd registered.

Adenocarcinoma

622 studies on the registry are indexed under Adenocarcinoma; 149 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

9 of the 53 studies in Adenocarcinoma with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 113 Adenocarcinoma studies recruiting now, 84 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 3 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Adenocarcinoma with a site in United Kingdom, or all of them as a file.
02

Study summary

In radiotherapy high-tech scans with x-rays (CT scans) are taken before and during treatment to locate the tumour and ensure the radiation is hitting the target.

These x-rays expose patients to additional radiation and the quality of these scans is often poor which makes it difficult to distinguish tumour from normal tissue and there may be uncertainty in the tumour position due to movement or shrinkage. To allow for these uncertainties a large margin around the tumour is also treated, but this means that large volumes of normal tissue also receive significant doses of radiation, which can result in early and late toxicity.

MRI (magnetic resonance imaging) is better than CT scanning at being able to tell the difference between tumour and normal tissues and does not expose patients to additional radiation. A new machine called an MR Linac (or magnetic resonance imaging-guided linear accelerator) integrates high quality MRI with a state-of-the-art radiotherapy machine and the Institute of Cancer Research (ICR)/The Royal Marsden Hospital (RMH) are currently installation a prototype, which will be one of the first in the world. This revolutionary technology has the potential to change the way radiotherapy is delivered. We hope the improved precision and accuracy in hitting the target will mean reductions in margins around tumours and that this will lead to higher cure rates with significantly fewer side effects. Studies are required to simulate treatment on the MR Linac before it can be used in routine clinical practice and to conduct these studies, we need to obtain MRI scans on volunteers and patients who are currently undergoing treatment. This study will involve imaging with MRI in healthy volunteers as well as in patient volunteers before and during their standard course of radiotherapy to allow us to develop MRI sequences derived on the MR Linac for MR Linac-based research focusing on clinical application and establishment into a MR-CT and MR only workflow, treatment adaptation and quality assurance.

Read the detailed description

This is a study protocol for the acquisition of MR Linac derived images with a view to MRIgRT for patients undergoing radiotherapy with radical intent at sites predicted to benefit most from MRIgRT (namely, for rectum, cervix, lung, prostate, bladder, breast, brain, oesophagus, head and neck, hepato-pancreato-biliary (HPB) and paediatric abdomino-thoracic cancers). These will be used to build a database of MR images for MR Linac-based research focusing on clinical application and establishment into a MR-CT and MR only workflow, treatment adaptation and quality assurance. The primary aims are to 1) develop MR Linac image sequences suitable for seeing tumour/target and normal tissue at the time of radiotherapy and 2) determine variations in image registrations and tissue contouring using the MR Linac images. Four stages of imaging development sub-studies will be included in this protocol for optimisation of MR imaging on the MR Linac. Consideration will be given to image quality, scan times, and IT requirements for reconstruction, storage and image transfer.

These imaging sub-studies will be:

A) Non-patient Volunteer Imaging Studies of Normal Tissue (n = 18 - 54 per centre). The four anatomical regions selected to be studied are Head and neck, Thorax (chest wall/breast and lung/oesophagus), Abdomen and Pelvis (male and female). Recruitment will continue until imaging from a minimum of three consecutive patients using the same 'exam card' are deemed to be acceptable for normal tissue visualisation for each anatomical site.

B) Patient Volunteer Imaging Studies of Normal Tissue (n = 39 - 72 per centre). We will further develop the protocols to visualise site specific tumours in 13 target areas (brain, oropharynx/larynx/hypopharynx, oesophagus, lung, chest wall _+/- regional lymph nodes), paediatric abdomen-thoracic cancers, hepatobiliary tract, bladder, gynaecology, prostate, rectum, oligomets bone and oliogmets soft tissue). Patients will be recruited for imaging for a minimum of one and maximum of 12 imaging sessions whilst undergoing radiotherapy planning and/or radiotherapy treatment. Repeat imaging will allow for the determination of protocol robustness. The aim will be to produce images appropriate for tumour and normal tissue visualisation with a view to directing radiotherapy. Recruitment will continue until imaging from a minimum of three consecutive patients using the same 'exam card' are deemed to be acceptable for tumour/target visualisation at each site.

C) Pathway development studies (n = 39 - 208 per centre). At each centre, it is estimated that 16 imaging sessions per tumour site are required for inter and intra registration observer variability. To establish library of images to be used to develop adaptive radiotherapy workflows, up to 50 imaging sessions may be required depending on the tumour site. Images for normal tissue and tumour visualisation will also be used to refine exam cards from Stage B.

This stage requires a minimum of three patient volunteers to be recruited to each tumour site which may (or may not) include images acquired in the previous Stage B of the study, and a maximum of 16 patient volunteers to reach the desired number of imaging sessions. Each volunteer should undergo a minimum of two and not more than twelve imaging sessions (max 1/day, 3/week). The methodology of image acquisition will follow methodology for Stage B as above. The primary aim will be to establish that both online and offline image-matching using MR Linac with a view to guiding radiotherapy treatments can be undertaken with minimal intra and inter user variability. Development of treatment workflow to help implement radiotherapy treatment on the MR Linac can also be carried out. Refined exam cards from Stage B but fine tuning as necessary can be used to acquire sets of images and to use this information to plan treatment by simulating an on-line treatment whilst not delivering radiation.

D) On-going image development and continuous quality improvement of images

This stage of the study can run in parallel, subsequent to or independently of stages B and C. The purpose will be to recruit patients receiving radiotherapy, non-radiotherapy cancer patients or non-patient volunteers in order to optimise MRI guided radiotherapy delivery. Examples of this include, investigating suitability of radiotherapy immobilisation devices for patient positioning and treatment set-up development and/or development of new/novel imaging sequences, optimisation of existing sequences and undertaking continuing image quality improvement for the tumour sites listed in this protocol. Adult patient with cancers not conventionally treated using radiotherapy could be recruited in order to investigate whether radiotherapy could be used as a treatment modality in the future. Patients with unusual or rare cancer (for example sarcoma, kidney and lymphoma) that do receive radiotherapy could be recruited to investigate the benefit of using the MR Linac for cancers of this type.

The total number of volunteers is, as yet, unknown; however the recruitment progress will be monitored by the trial management group (TMG). The TMG will ensure that this protocol is being adhered to, that all volunteers are being imaged safely and that the information gained from the imaging sessions is being used appropriately. The investigator may recruit between one and five volunteers (patient, non- radiotherapy patient or non patient). On going evaluation of technique MRI sequence and/or equipment etc should be carried out to determine number of required volunteers with a maximum of 5 repeated imaging sessions per volunteer. The TMG can restrict the maximum number of volunteers and repeated imaging sessions, if appropriate.

A maximum of 150 volunteers will be recruited to this section of the study

03

Conditions studied

  • Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

There are 4 groups of participants:

A) Non-patient volunteers who will take part in non-patient volunteer imaging studies of normal tissue.

B) Patient volunteers who will take part in imaging studies of normal tissue. C) Patient volunteers who will take part in pathway development studies. D) non patient and patient volunteers who will take part in on going image development and continuous quality improvement of images

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All volunteers must undergo and satisfy MRI safety screening
  • Non-patient volunteers must have no known (or suspected) significant medical condition and be 18 years of age
  • Patient volunteers must have confirmed invasive carcinoma of the tumour/target sites listed in this protocol and be under the care of a Clinical Oncologist at the Royal Marsden NHS Foundation Trust or The Christie NHS Foundation Trust and patients be planned to receive radiotherapy to target site to be imaged
  • All volunteers must be willing and able to provide /assent for the study
  • Paediatric patient volunteers between the ages of 3 and 18 years, will have consent provided by his or her legal guardian who is 18 years of age
  • Have an (ECOG) performance status of 0-1

Exclusion criteria

Exclusion Criteria:

Any conditions that would be a to MRI including:

  • Failure to satisfy the MRI safety screening
  • Implanted pacemakers and/or pacing wires
  • Cochlear implants
  • Programmable hydrocephalus shunts
  • Implanted neurostimulation systems
  • Implanted drug infusion pumps
  • Ferromagnetic implants And additional conditions that may place volunteers at increased risk from MRI procedures including:
  • Known susceptibility to seizures or migraines
  • Fever, reduced thermal regulatory capabilities or increased sensitivity to raised body temperature (for example pregnant women)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
173 participants (estimated)
Patient registry
No

Groups and cohorts

  • A) Volunteer Imaging Studies

    Non-patient Volunteer Imaging Studies of Normal Tissue (n = 18 - 54) per centre In the first stage, participants will be non-patient volunteers who agree to undergo MR imaging on the MR Linac on a single or multiple occasions (up to 12) to examine the anatomic sites listed above for normal tissue visualisation.

    Procedure: Imaging

  • B) Patient Volunteer Imaging Studies

    Patient Volunteer Imaging Studies of Normal Tissue (n = 39 - 72 per centre) In the second stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine multiple tumour sites (n=11) for tumour/target visualisation.

    Procedure: Imaging

  • C) Pathway development studies

    Pathway development studies (n = 39 - 208 per centre) In the third stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine intra and inter observer variability on target and organs at risk visualisation using the exam cards from Stage B.

    Procedure: Imaging

  • D) On going imaging development & quality improvement

    This stage of the study will run in parallel or subsequent to stages B and C. The purpose will be to recruit patient or non-patient volunteers to help optimise MR guided radiotherapy delivery e.g. investigate radiotherapy immobilisation and equipment for patient positioning and set up development and/or development of new/novel imaging sequences, optimisation of existing sequences and undertaking continuing image quality improvement.

    Procedure: Imaging

Interventions

  • ProcedureImaging

    This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.

06

What researchers measure

Primary outcomes

  1. Acceptability of the quality of imaging sequences assessed by a Visual Grading Analysis (VGA) (Stages A and B)

    Time frame: 12 months to build exam cards. Information gained after each cohort is recruited will build up in the definition of protocol imaging

  2. Inter observer registration variability (Stage C) based on the production of images of sufficient quality to allow for imaging matching and registration (assessed by validated image quality grading system)

    Time frame: Assessment will be done for each imaging sequence available for each patient at each time point for imaging aquired up to one year.

Secondary outcomes

  1. Intra observer registration variability (Stage C) to assess the inter observer variability in assessment of tumour position between 4 assigned observers (target: a SD of variation of less than 3mm)

    Time frame: Assessment will be done for each imaging sequence available for each patient at a specific time point. Up to 2 year recruitment period.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Goodburn R, Bruijnen T, Lecoeur B, Nair P, Ahmed M, Barnes H, Oelfke U, Wetscherek A. Gradient system characterization of a 1.5 T MR-Linac with application to 4D UTE imaging for adaptive MR-guided radiotherapy of lung cancer. Magn Reson Med. 2025 Jul;94(1):28-40. doi: 10.1002/mrm.30505. Epub 2025 Mar 19. PubMed 40106794 ↗
  • Clough A, Pitt E, Nelder C, Benson R, McDaid L, Whiteside L, Davies L, Bridge J, Freear L, Chuter R, Berresford J, McPartlin A, Crockett C, Cobben D, Salem A, Faivre-Finn C, Huddart R, Eccles CL. Simultaneous implementation of unrelated tumour sites on the MR Linac: A review of the commissioning process from a radiographer perspective and lessons learned. J Med Imaging Radiat Sci. 2024 Dec;55(4):101728. doi: 10.1016/j.jmir.2024.101728. Epub 2024 Aug 16. PubMed 39153404 ↗
  • Clough A, Chuter R, Hales RB, Parker J, McMahon J, Whiteside L, McHugh L, Davies L, Sanders J, Benson R, Nelder C, McDaid L, Choudhury A, Eccles CL. Impact of a contouring atlas on radiographer inter-observer variation in male pelvis radiotherapy. J Med Imaging Radiat Sci. 2024 Jun;55(2):281-288. doi: 10.1016/j.jmir.2024.03.004. Epub 2024 Apr 11. PubMed 38609834 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2017 (actual). Primary completion is estimated for Dec 2026, 110 months after the start.

Of 44 observational studies under Adenocarcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 114. This study's planned 110 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2016
First posted
Nov 25, 2016
StartActual
Oct 17, 2017
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
3 publications citing this study linked from PubMed, e.g. PubMed 40106794 ↗
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Publications 3 publications citing this study linked from PubMed, e.g. PubMed 40106794 ↗
    + 5 other changes: index terms, verification date, oversight details, description and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02973828
Responsible party
Sponsor
First posted
Nov 25, 2016
Start date
Oct 17, 2017
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 6, 2026

Study contacts

Greta Bucinskaite
Contact
greta.bucinskaite@rmh.nhs.uk
+44 20 3186 5157
Robert Huddart
principal investigator · Institute of Cancer Research, United Kingdom

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion